Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Brolucizumab-Dbll intravitreal injection
Aflipercept intravitreal injection
INMC
Abu Dhabi, United Arab Emirates
RECRUITINGBest corrected visual acuity (BCVA)
Change in BCVA in LOG MARS(logarithm minimum angle of resolution
Time frame: 12 months
Tarek Elhamaky, MD
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.